Evidence map›Paper›PMID 42857647›Full record

ArticleThe Lancet regional health. Southeast Asia2026

Seven-day versus fourteen-day low-dose primaquine for

Rajendra Kumar Baharia, Sauman Singh-Phulgenda, Syed Mohammad Naser, Apoorv Gupta, Rutuja Chhajed, Mohammad Sharif Hossain, Karmveer Yadav, Reena Verma, Salil Kumar Pal, Parinita Halder Ranjit and 20 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Lancet regional health. Southeast Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Rajendra Kumar BahariaICMR- National Institute of Malaria Research Field Unit, Nadiad, Gujarat, India.
Sauman Singh-PhulgendaWorldWide Antimalarial Resistance Network (WWARN), Oxford, UK.
Syed Mohammad NaserCalcutta National Medical College, Kolkata, West Bengal, India.
Apoorv GuptaICMR-National Institute of Malaria Research, Sector 8, Dwarka, Delhi, 110077, India.
Rutuja ChhajedWorldWide Antimalarial Resistance Network (WWARN), Oxford, UK.
Mohammad Sharif HossainInternational Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Karmveer YadavICMR-National Institute of Malaria Research, Sector 8, Dwarka, Delhi, 110077, India.
Reena VermaICMR-National Institute of Malaria Research, Sector 8, Dwarka, Delhi, 110077, India.
Salil Kumar PalCalcutta National Medical College, Kolkata, West Bengal, India.
Parinita Halder RanjitCalcutta National Medical College, Kolkata, West Bengal, India.
Bhavin SolankiAhmedabad Municipal Corporation, Ahmedabad, Gujarat, India.
Kamlesh Jayantilal UpadhyayBJ Medical College, Ahmedabad, Gujarat, India.
Leena DabhiAhmedabad Municipal Corporation, Ahmedabad, Gujarat, India.
Rajesh SharmaAhmedabad Municipal Corporation, Ahmedabad, Gujarat, India.
Subrata Roy ChowdhuryKolkata Municipal Corporation, Kolkata, West Bengal, India.
Amitava ChakravortyKolkata Municipal Corporation, Kolkata, West Bengal, India.
Megha RajasekharCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
Grant LeeGlobal and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia.
Hellen MnjalaGlobal and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia.
Souvik GhoshCalcutta National Medical College, Kolkata, West Bengal, India.
Sunitaben S ParmarICMR- National Institute of Malaria Research Field Unit, Nadiad, Gujarat, India.
Debjani SenguptaCalcutta National Medical College, Kolkata, West Bengal, India.
Anup AnvikarICMR-National Institute of Malaria Research, Sector 8, Dwarka, Delhi, 110077, India.
Philippe J GuerinWorldWide Antimalarial Resistance Network (WWARN), Oxford, UK.
Ric N PriceCentre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
Manju RahiICMR-Vector Control Research Centre, Puducherry, India.
Praveen K BhartiAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
Kamala ThriemerGlobal and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia.
Nitika NitikaAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
Robert J CommonsGlobal and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia.

Funding

Bill & Melinda Gates Foundation INV-004713
6 · The paper itself

Abstract

Background: India has a high burden of Methods: We conducted an open label, non-inferiority, randomised controlled trial at two sites in India. Febrile patients older than 16 years with microscopically confirmed Findings: Between September 2023 and October 2024, a total of 400 patients were enrolled (201 randomised to the 7-day group and 199 to the 14-day group). By 180 days of follow up, there were a total of four Interpretation: Compared with a 14-day primaquine regimen, a 7-day regimen of 3·5 mg/kg was well-tolerated and non-inferior within the observed 180 days of follow up. Adherence was greater among patients in the 7-day regimen. Although the overall number of recurrences was lower than anticipated, limiting the precision of the estimates, these findings are consistent with and support the current WHO recommendation for a 7-day primaquine regimen. Future studies with longer follow up could provide additional evidence for efficacy of this regimen against late Funding: Infectious Diseases Data Observatory (University of Oxford) through a grant from the Bill & Melinda Gates Foundation (INV-004713).

Indexed as

Glucose-6-phosphate dehydrogenase deficiencyMalariaMulticentre randomised trialPlasmodium vivaxPrimaquine

Identifiers

PMID42857647
PMCPMC13651684

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.